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Abstract
Recently, the term "inflammaging" was coined by Franceshci and colleagues to characterize a widely
accepted paradigm that ageing is accompanied by a low-grade chronic up-regulation of certain pro-
inflammatory responses. Inflammaging differs significantly from the traditional five cardinal features
of acute inflammation in that it is characterized by a relative decline in adaptive immunity and T-
helper 2 responses and is associated with increased innate immunity by cells of the mononuclear
phagocyte lineage. While the over-active innate immunity characteristic of inflammaging may
remain subclinical in many elderly individuals, a portion of individuals (postulated to have a "high
responder inflammatory genotype") may shift from a state of "normal" or "subclinical" inflammaging
to one or more of a number of age-associated diseases. We and others have found that IFN-γ and
other pro-inflammatory cytokines interact with processing and production of Aβ peptide, the
pathological hallmark feature of Alzheimer's disease (AD), suggesting that inflammaging may be a
"prodrome" to AD. Although conditions of enhanced innate immune response with
overproduction of pro-inflammatory proteins are associated with both healthy aging and AD, it is
suggested that those who age "well" demonstrate anti-inflammaging mechanisms and biomarkers
that likely counteract the adverse immune response of inflammaging. Thus, opposing the features
of inflammaging may prevent or treat the symptoms of AD. In this review, we fully characterize the
aging immune system. In addition, we explain how three novel treatments, (1) human umbilical cord
blood cells (HUCBC), (2) flavanoids, and (3) Aβ vaccination oppose the forces of inflammaging and
AD-like pathology in various mouse models.
Introduction
Some two thousand years ago, Celsus first described 4 car-
dinal signs of inflammation: (1) redness, (2) swelling, (3)
heat, and (4) pain. Shortly thereafter a fifth sign, loss of
function, was added by Galen. Recently, the term "inflam-
maging" was coined by Franceshci and colleagues to char-
acterize a widely accepted paradigm that ageing is
accompanied by a low-grade chronic up-regulation of cer-
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tain inflammatory responses [1-8]. Inflammaging differs
significantly from the traditional five cardinal features of
acute inflammation in that it is a (a) low-grade, (b) con-
trolled, (c) asymptomatic, (d) chronic, and (e) systemic
state of inflammation [9]. This systemic inflammatory
response is evidenced by increased serum levels of pro-
inflammatory cytokines (IL-6, IL-15, IL-8) [10-15] and
other inflammatory biomarkers, such as coagulation fac-
tors [16-18]. Additionally, subclinical infection with com-
mon viruses such as cytomegalovirus (CMV) is a hallmark
feature of inflammaging. There also may be a genetic com-
ponent, as suggested by studies on alleles coding for medi-
ators of inflammation including cytokines and
coagulation factors [19-21]. Finally, reactive oxygen spe-
cies (ROS) cause amplification of cytokine release, fueling
a self-perpetuating positive feedback loop. The end result
of this cycle is a chronic and systemic pro-inflammatory
state where both tissue damaging and healing mecha-
nisms operate simultaneously. Over decades, the oppos-
ing forces are likely critical perpetrators of ageing and age
related disease, leading to an accumulation of subtle tis-
sue damage [3,5-8].
Inflammaging is characterized by a relative 
decline in adaptive immunity and T-helper 2 
responses and is associated with increased cell 
mediated responses
According to Franceschi's original description of inflam-
maging, innate immunity progresses to a chronically
active state secondary to exhaustion of the more evolu-
tionary recent adaptive (specific) immune system [22].
This exhaustion is in large part due to age-associated
reduction of T-cells for various reasons including thymic
involution [23-25], as well as fewer bone marrow early
progenitor B cells [26]. In early life, naïve T cells are acti-
vated by contact with antigens. They then differentiate
into effector or memory cells. Because the quantity of T-
cells in healthy individuals is stable over the adult
lifespan, peripheral T cell turnover of pre-existing popula-
tions in the thymus is required for replacement of T cells
in relatively young individuals [27-30].
Together with the diminution of adaptive immunity that
occurs in inflammaging, there is also an increase in the
number of antigen-experienced cells and a decrease in the
number of naïve T cells in the circulation, which results in
accumulation of incompetent memory lymphocytes [31].
These cells likely clonally expanded and became effector
memory T-cells that were competent at one time, but then
lost their antigen-specific function due to their age. This
phenomenon is believed to be owed to life-long antigenic
stress from immunosurveillance against persistent viruses,
especially CMV [32]. This accumulation of a limited rep-
ertoire of "megaclones" of effector memory CD8+ T cells
results from long-term, chronic exposure to antigens over
time frames much longer than during evolution of the
human immune system [28,33-39]. The net result of this
is (1) to reduce adaptive immunity to previously encoun-
tered pathogens, and (2) to weaken the host adaptive
immune response to novel pathogens due to a reduction
in the diversity of the antigen-recognition repertoire with
age. In fact, based on analysis of human T-cell receptor
(TCR) Vβ chain usage, the antigen-recognition repertoire
decreases from approximately 108 in young adults to 106
in the elderly [40]. Moreover, CD8+ T-cells in the elderly
display significantly decreased ability to secrete inter-
feron-gamma (IFN-γ) when stimulated by cognate antigen
in comparison to younger age groups [36,38]. Also, naïve
CD4+ T-cells from old humans and mice show decreased
responsiveness to TCR stimulation and altered profiles of
cytokine production versus naïve CD4+ T-cells from young
hosts. Likewise, the helper function of naïve CD4+ T-cells
for antibody production by B cells is also decreased [41].
The decline in responsiveness of naïve CD4+ T cells is due
to the chronologic age of the cells themselves, and not of
the individual host [41], suggesting that long-term main-
tenance of naïve CD4+  T-cells through homeostatic
cytokines may not have a positive impact on their func-
tion. Indeed, naïve CD4+ T-cells that have undergone
homeostatic cell divisions proliferate less and secrete less
IL-2 in response to antigen than do naïve CD4+ T-cells
that have not undergone homeostatic division [41].
Unlike naïve lymphocytes, memory CD4+ T lymphocytes
are long-lived and relatively competent with age. These
antigen-experienced T-cells, when isolated from healthy
elderly humans and healthy old mice, respond normally
to antigen-induced proliferation in vitro [42] and those
generated at a young age respond well to antigens over
time. Conversely, naïve CD4+ T-cells derived in old age
respond poorly [43]. Together, these studies point to an
age-associated defect in memory CD4+ T cells which may
originate from defects of aged naïve CD4+ T-cells that have
reduced clonal diversity and proliferation potential. Inter-
estingly, changes of the ratio of memory to effector CD4+
T-cell subsets with age have also been implicated in defi-
cient adaptive immune responses to viral infections and
vaccines [44].
An additional important feature of inflammaging which
contributes to defective T-cell function and adaptive
immunity is accumulation of CD28-CD8+ T-cells and the
loss of naïve CD8+ T-cells. These T-cells are absent in new-
borns while composing some 85% of circulating CD8+ T-
cells in the elderly. The accumulation of CD28-CD8+ T-
cells was also shown in patients with viral infections such
as CMV [45]. CD28-CD8+ T-cells may signify terminal dif-
ferentiation from the CD28+CD8+ subset after repeated
antigenic stimulation. Functionally, CD28-CD8+ T-cells
have a reduced proliferative response to TCR stimulationJournal of Neuroinflammation 2008, 5:51 http://www.jneuroinflammation.com/content/5/1/51
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but exhibit normal or even enhanced cytotoxic capacity
and are resistant to apoptosis [46]. Furthermore, several
studies have demonstrated the virtual disappearance of
naïve CD8+ T-cells in the elderly associated with a signifi-
cant increase in the proportions of differentiated effector
memory and effector CD8+  T-cells in comparison to
younger individuals. Interestingly, most of these cells in
the elderly do not have short telomeres. Taken together,
these data suggest that, over the course of life, these T-cell
populations have undergone a process of end-stage differ-
entiation and that persistent infection with common
pathogens, such as CMV, induces chronic stimulation of
specific T cells that leads to terminal differentiation to
senescent cells with an altered functional capability
[30,47-50]. Further, it seems that clonal expansion of
CD28-CD8+T-cells seems directly responsible for
increased infection rates and the common failed response
to vaccines in the elderly [51].
Decreased adaptive immunity characteristic of inflam-
maging also involves changes in the B-cell repertoire not
unlike those observed in the T-cell pool [52-54,54]. The
quality of the humoral immune response is decreased
with age owing to low serum immunoglobulin concentra-
tions and low numbers of antigen-specific, immunoglob-
ulin-secreting plasma cells. Further, antibody specificity,
isotype and affinity changes are typical features of old age
[54]. For example, immunoglobulins produced in aged
mice have lower affinity and are less protective versus
those of young animals [55]. This may be secondary to
aging's adverse effects on the germinal centre reaction in
secondary lymphoid tissues [56], and leads to a dimin-
ished quantity of germinal centres in response to tetanus
toxoid stimulation [57]. The quantity of B cells also
decreases in the elderly (58). At the cellular level, altera-
tion in immunoglobulin generation (through class
switching) in B cells is observed in aged individuals [59],
which may contribute to the decline of the adaptive
immune response in the elderly. Also, age is positively
associated with B cell malignancies in older adults with
oligoclonally expanded B cells [30].
The weakened adaptive immune responses characteristic
of inflammaging may also be caused by deficient MHC
class II antigen presentation by dendritic cells (DCs) and
macrophages, or in the case of the brain, microglia
[60,61]. Although these cells are part of the innate
immune system, they are critical for initiation of adaptive
immunity. That is, activation of these phagocytic cells via
pattern recognition receptors (PRRs), such as toll-like
receptors (TLRs), mediates their maturation and migra-
tion to secondary lymphoid organs where they present
antigens to T-cells [62,63]. Studies have indicated that this
diminished MHC class II expression over the life span is
typical in both humans and mice [64,65]. Not only do
innate immune cells down-regulate MHC II, but
decreased numbers of Langerhans cells (LCs; the DCs of
the skin) have been observed consistently in both elderly
humans and old mice. LC migration to lymph nodes is
also decreased in old mice; possibly secondary to reduced
availability of IL-1β, a cytokine which provides autocrine
stimulus for migration and induces TNF-α production by
adjacent keratinocytes, which also promotes LC mobiliza-
tion [66]. Additionally, DCs from elderly people may
under-express costimulatory receptors and IL-12, thus
impairing their ability to induce effector T-cell differentia-
tion. In addition, the production of IL-10 is elevated in
elderly individuals and may inhibit DC maturation and
macrophage function [60]. Further, it was also demon-
strated that IFN-γ-mediated induction of the MHC II gene
(H2-Ab1) is impaired in macrophages from aged mice due
to the decreased binding of transcription factors to the
promoter [64]. This lack of proper activity of the innate
arm of immunity has also been associated with upregu-
lated pro-inflammatory responsiveness. That is, activated
macrophages from aged humans and mice produce higher
amounts of the proinflammatory paracrine molecule
prostaglandin E2 than younger individuals, which inhib-
its surface expression of MHC class II [65]. In addition, we
also found proinflammatory activation of mouse micro-
glia inhibits their ability to phagocytose Alzheimer's amy-
loid-beta (Aβ) peptide [67].
Coincident with this phenomenon, either due to a
"release" of adaptive control on innate immunity and/or
a compensatory mechanism for lack of effectiveness of
adaptive immunity, is over-activation of certain pro-
inflammatory responses [4,7,22] by mononuclear phago-
cytes (cells of the innate immune system) [68]. These cells
are the first to arrive at sites of infection or tissue damage.
Their physiologic role is to initiate an inflammatory
response, phagocytose the pathogen or foreign body,
recruit natural killer (NK) cells, and facilitate the terminal
differentiation and migration of DCs that will modulate
the T cell-mediated adaptive immune response. [32].
These cells, including neutrophils and macrophages, acti-
vate innate immunity via their PRRs [69] which induce a
pro-inflammatory response via downstream nuclear fac-
tor-kappa beta (NF-kβ) and mitogen associated protein
kinase (MAPK) signaling [70,71]. Indeed, studies in both
elderly humans and old mice substantiate the notion that
inflammaging constitutes a gradual loss of adaptive and
increased activity of mononuclear cell innate immunity
demonstrated by pro-inflammatory cell responses to
mitogens [30,32]. For example, peripheral blood mono-
cytes from elderly individuals generated higher amounts
of tumor necrosis factor alpha (TNF-α) and interleukin 1
beta (IL-1β) in comparison to cells from young subjects
[72]. Furthermore, the data regarding cytokine and chem-
okine secretion in several studies using human monocytesJournal of Neuroinflammation 2008, 5:51 http://www.jneuroinflammation.com/content/5/1/51
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from aged or young individuals activated in vitro with
mitogens or the bacterial endotoxin lipopolysacharride
(LPS), for the most part, demonstrate an increase in the
levels of pro-inflammatory factors such as IL-6 and IL-8
[73-79]. As noted above, activated macrophages from
aged mice and humans produce more prostaglandin E2
than younger individuals, and this proinflammatory
coagulation factor suppresses IL-12 secretion, decreases
APC surface expression of MHC II, and enhances IL-10
secretion which inhibits T-cell function. This increased
prostaglandin E2 is due to enhanced expression of induc-
ible cyclooxygenase [80]. We suggest that, underlying this
increased proinflammatory signaling by mononuclear
cells of the innate immune system is the previously men-
tioned increase in the number of antigen-experienced T
cells and the decrease in the number of naïve cells in the
elderly. The antigen-experienced T cells (observed as large
oligoclonal expansions which dominate the repertoire)
have lost the important costimulatory molecule CD28
and have a polarized pro-inflammatory T-helper 1 (Th1)
profile [81]. Cytokines derived from Th1 cells are associ-
ated with cell mediated pro-inflammatory responses,
while Th2 cytokines act on B cells to enhance adaptive
immune responses (including antibody production) by
promoting activation and differentiation. Importantly, an
imbalanced Th1/Th2 ratio can change the cytokine micro-
environment in lymphatic tissues and trigger the chronic
pro-inflammatory innate immune processes characteristic
of inflammaging [22]. It is important to note that there are
conflicting reports on the basic notion that an imbalance
in Th1/Th2 immunity is best characterized in the elderly
by overactive Th1 and underactive Th2 cytokine produc-
tion. For instance, the production of the Th1 cytokine
IFN- has been reported to be high [82,83] or low [84-87]
during aging. Such discrepancies may result from varia-
tions among species, strains, organs, culture systems, or
inter-individual differences during the course of the aging
process. To circumvent such confounds, studies focusing
on provoking an antigen-specific immune response, for
example by vaccination, have proved powerful. For exam-
ple, influenza vaccination induces protective antibodies
in only 40–70% of the elderly [88,89]. Saurwein-Teissl
and colleagues (2002) analyzed a very homogenous
"model" cohort of elderly persons, none of whom pro-
duced specific antibodies one month after influenza vac-
cination. Using this homogenous cohort, the lack of
antibody production following immunization was posi-
tively associated with the increased occurrence of the
expanded CD8+CD28- T cell subset. These clones, which
produce large amounts of IFN-γ, are strongly suggested to
be the basis for a change in the polarization of the
immune system toward a Th1 profile in elderly persons
and the development of age-related immune deficiency
[90]. Moreover, we would suggest that the response to a
vaccine may be used as an assessment of inflammaging,
and thus risk for age-related disease.
As further detailed below, proinflammatory cytokines
associated with reduced adaptive and upregulated innate
mononuclear cells (an integral feature of inflammaging)
are now believed to exacerbate the pathology and disease
course of age-related disorders including Alzheimer's dis-
ease (AD) [91-93]. For example, IFN-γ in combination
with TNF-α triggers the production of Aβ peptide in
human neuronal and extraneuronal cells [3] and increases
the production of ROS by microglia. TNF-α can also fur-
ther exacerbate Aβ toxicity [4].
Does inflammaging perpetrate and/or 
exacerbate AD?
While the over-active innate immunity characteristic of
inflammaging may remain sub-clinical in many elderly
individuals for the reasons stated above, a portion of indi-
viduals (postulated to have a "high responder inflamma-
tory genotype") may shift from a state of "normal" or
"subclinical" inflammaging to one or more of any age-
associated diseases. Simultaneously, aging is associated
with an increase in production of oxygen-derived radicals,
i.e., reactive oxygen species (ROS), with a concurrent
decrease in the ability to defend against ROS. Indeed,
many works have established oxidative stress and damage
not only in the lesions of AD but also in neurons at risk of
death [94-100].
It is interesting to note that Alois Alzheimer himself first
noted what he termed "gliose" (English translation: gliosis,
or inflammation of glia) when characterizing brain
pathology in 1907 in the first AD case. Indeed microglia
are the common source of pro-inflammatory and oxida-
tive stress in AD as shown by consistent gross observations
of upregulated inflammatory responses in brain (includ-
ing products of activated microglia and astrocytes) regions
that exhibit high levels of AD pathology such as the fron-
tal and limbic cortices [101-103]. Conversely, these mark-
ers of inflammation or oxidative stress are absent or
minimal in brain regions which are typically less suscepti-
ble to AD pathology, such as cerebellum. Upon analysis,
inflammatory mediators and signs of oxidative stress are
most robustly observed in regions of Aβ deposits and neu-
rofibrillary tangles (NFT), classical AD hallmarks often
associated with neurodegeneration [104]. For example,
significant increases of an oxidized nucleoside derived
from RNA, 8-hydroxyguanosine (8OHG), and an oxi-
dized amino acid, nitrotyrosine, have been demonstrated
in vulnerable neurons of AD patients [105]. Importantly,
it was shown that oxidative damage is quantitatively great-
est early in the disease and reduces with disease progres-
sion. Interestingly however, increases in Aβ deposition
were associated with decreased oxidative damage [105].Journal of Neuroinflammation 2008, 5:51 http://www.jneuroinflammation.com/content/5/1/51
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Moreover, neurons with NFT show a 40%–56% decrease
in relative 8OHG levels compared with neurons free of
NFT. We would suggest that inflammaging involves
increased oxidative damage prior to a diagnosis of AD (or
at least early in AD [105,208] due to over-activation of cer-
tain pro-inflammatory responses [4,7,22] by mononu-
clear phagocytes (cells of the innate immune system) [68].
As AD worsens, amyloid deposition increases simultane-
ously with compensatory changes that reduce damage
from ROS, which could include disregulation of T-cell
responses [106]. This is further supported by findings in
Tg2576 AD transgenic mice in which oxidative stress pre-
cedes Aβ deposition [107]. Also supporting this notion,
patients with MCI or very mild AD show increased levels
of lipid peroxidation and nucleic acid oxidation in post-
mortem brain, CSF, plasma, urine and peripheral leuko-
cytes in conjunction with decreased levels of plasma
antioxidants and total plasma antioxidant capacity [108-
110].
Perhaps the most important piece of evidence to substan-
tiate the pathogenic importance of inflammaging in AD
comes from patients without history of dementia but who
nonetheless exhibit sufficient Aβ/NFT at autopsy to other-
wise qualify an AD diagnosis (so-called "high pathology
controls") [111]. Interestingly, these patients demonstrate
only modest elevations of proinflammatory markers com-
pared with typical non-demented patients but dramati-
cally less than AD patients [112]. Furthermore, there is a
plethora of evidence indicating direct inflammatory toxic-
ity in AD brain. For example, assembly of complement
components ultimately leading to membrane attack com-
plex formation and lysis of neuronal cells has been shown
ultrastructurally [113]. In seeking to elaborate and extend
upon the original theories postulated by Franceshci, it
appears that inflammaging may serve as a prodrome or an
exacerbating factor for development of AD [9,22]. Under-
standing AD in this context may shed new light on immu-
nological treatment targets for AD, which may also apply
to other neurodegenerative diseases including HIV associ-
ated dementia (HAD), Parkinson's Disease, and Multiple
Sclerosis (MS).
Conditions of enhanced innate immune response with
overproduction of pro-inflammatory proteins are associ-
ated with both healthy aging and AD [114-116]. The dif-
ference between these groups seems to be that those who
age "well" demonstrate anti-inflammaging mechanisms
and biomarkers that likely counteract the adverse immu-
nity characteristic of inflammaging. For example, it seems
that centenarians demonstrate anti-inflammatory
responses which may delay or even stop emergence of
many age-related diseases [9,117,118]. Some examples in
centenarians are as follows: reduction of pro-inflamma-
tory, pro-atherosclerotic properties of platelets [119],
increased resistance to inhibitory actions of homocysteine
on nitric oxide generation [119], low plasma membrane
lipid peroxide levels, high membrane fluidity with normal
content of sialic acid [120-123] and increased plasma cor-
tisol, one of the most potent anti-inflammatory molecules
[124,106]. Further, an example of a genetic anti-inflam-
maging mechanism in centenarians is increased frequency
in males of the IL-10-1082GG genotype, which is associ-
ated with high production of this important anti-inflam-
matory cytokine [125]. Conversely, the same genotype is
much less frequent in patients affected by AD [126]. Thus,
it is believed that individuals who carry such "high
responder" genotypes may suffer from diseases in which
inflammaging could be a key eitiological disease compo-
nent. This notion is supported by many studies indicating
an increase of inflammatory parameters, such as comple-
ment factors, proinflammatory cytokines, and activation
of microglia co-localized with amyloid plaques in the AD
brain [127].
Others have also reported what would seem to be biomar-
kers of inflammaging in AD. One of these markers is
neopterin, a blood compound produced by monocyte-
derived macrophages upon stimulation with IFN-γ.
Although it is virtually impossible to determine whether
activation of the innate or acquired arms of the immune
system is primary based on measurements of neopterin,
in contrast to the well known marker of systemic immune
activation, c-reactive protein (CRP), neopterin seems to be
more associated with cell-mediated responses and is com-
monly used as a biomarker for this purpose [128,129].
Three studies to date have shown elevated levels of neop-
terin in AD patients compared to age-matched controls
[130-132]. The authors suggest this elevated neopterin
may be a vestigial result of serum immunity to CMV. That
is, in the AD patients, 70% were positive for CMV anti-
body and CMV antibody concentrations correlated with
concentrations of neopterin and CRP. As previously men-
tioned, CMV infection seems to be a critical factor in the
diminution of adaptive immunity in the elderly as it con-
fers expansion of a limited repertoire of CD8+ T cells,
which afterward lack full functionality [45,90]. A similar
response to influenza vaccination in the elderly was
described [90]. Thus, it has been proposed that enhanced
cell-mediated innate immunity reflected by neopterin
production in AD patients might be secondary to senes-
cence of CMV-expanded T-cell clones [114]. It is of course
difficult to determine from these clinical studies whether
such factors as neopterin, CRP, and humoral responses
are etiologically involved in AD, but it certainly appears
that there is a positive correlation between these factors
and AD.
Several studies have examined T-cell populations and acti-
vation markers in AD in peripheral blood (for a review seeJournal of Neuroinflammation 2008, 5:51 http://www.jneuroinflammation.com/content/5/1/51
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188). Although total percentage of T-cells was not found
to be altered [133,134], alterations of their function, dif-
ferentiation and subset distribution have been demon-
strated. Abnormal functioning of suppressor as well as Th
cells has been described in AD patients [135,136]. Signif-
icantly decreased activation response of this adaptive
immune cell in AD compared to age-matched controls has
also been observed. The proliferative response of T-cells in
AD seems reduced; however, this was not universally
observed. While two studies found no alterations in the
proliferative response of AD patient T-cells [137,138],
four studies report a decrease in proliferation of AD
patient T-cells [139-141]. Most recently, one study [109]
found a significant decrease of CD3+ T lymphocytes and
CD19+ B lymphocytes in AD patients. A slight increase of
the CD4+ and a decrease of the CD8+ subpopulation was
also observed, but this was not accompanied by a signifi-
cant change in the CD4+/CD8+ ratio, and CD16+CD56+
cells were not altered. Schindowski and colleagues found
increased apoptosis in CD4+ T cells as well as NK cells in
AD patients, while in aged individuals, all subsets were
affected. This may be explained by the levels of Bcl-2 in T-
cells, which were significantly increased in patients with
mild AD. Apoptosis and Bcl-2 levels were also elevated in
the APP751SL × PS1M146L transgenic mouse model of AD
[142]. Together, these finding suggest a diminution of
adaptive immunity reflected by dysregulated and altered
T- cell distributions in AD [127]. However, as mentioned
above, it is difficult to conclude from these clinical studies
whether such alterations in the leukocyte repertoire of AD
patients are etiologically involved in disease progression
or simply epiphenomena. For this reason, future studies
in mouse models of AD deficient in key innate/adaptive
immune/inflammatory molecules will be important.
In vitro and in vivo studies by us and other groups suggest
that IFN-γ and other pro-inflammatory cytokines interact
with processing and production of the Aβ peptide
[143,144]. For example, IFN-γ is a strong stimulator of
Aβ1–40 and Aβ1–42 production in vitro in neurons and in
other brain cells [143,144]. Even if IFN-γ produced in the
periphery does not directly affect brain Aβ levels,
increased peripheral production of Aβ at sites where IFN-
γ levels are elevated might influence Aβ levels in the brain
[145,146]. Thus, we and others have proposed adverse
effects of altered immunity (upregulated innate mononu-
clear cell immunity/Th1 cytokine secretion and downreg-
ulated adaptive immunity) in AD patients, and this has
led us and others to focus on three diverse treatment
modalities in AD transgenic mice models which seem to
"re-balance" pro- versus anti-inflammatory responses in
the AD brain. These therapies are: (1) non-steroidal anti-
inflammatory drugs (NSAIDs), (2) Aβ immunization, (3)
human umbilical cord blood cells (HUCBC), and (4)
plant-derived compounds known as flavonoids.
Finally,, we suggest that that inflammaging as a prodrome
to AD fits well with the "2-hit hypothesis" of AD put forth
by Zhu and colleagues stating that both oxidative stress
and mitogenic dysregulation are necessary and sufficient
to cause AD [147]. The first "hit" required for AD develop-
ment is suggested to be the above discussed oxidative
stress during MCI and early in the course of AD. This goes
hand in hand with upregulation of innate immunity as
part of inflammaging. The second "hit" is also suggested
to occur during this same prodromal time period during
inflammaging and disregulation of neuronal mitotic pro-
teins [148,149]. Indeed, cell cycle markers occur prior to
the appearance of gross cytopathological changes in AD
[150]. In further support of this idea, mitotic events have
been shown to occur in pre-AD patients with MCI which
represents a time point where inflammaging effects are
near their maximum, ie during the prodromal stage of AD
[151].
Re-balancing innate and adaptive immunity as a 
treatment paradigm for AD NSAIDs and Aβ 
immunization: from mice to humans
Several observational studies [152-154] have shown that
use of various anti-inflammatory agents is associated with
reduced risk of developing AD. After preliminary studies
produced encouraging results with nonsteroidal anti-
inflammatory drugs (NSAIDs) for AD treatment,
[155,156] a series of larger studies were launched that
tested glucocorticoid therapy, [157] NSAIDs, [158-160]
and hydroxychloroquine [161] on patients with AD and
MCI and also cognitively normal individuals at risk for
AD. The results of these trials to date have been negative.
None of the NSAIDs tested in early trials had amyloid-
reducing activity. Newer NSAIDS including LY450139
[162,163] and R-flurbiprofen [164] do have this activity.
LY450139, given in doses ranging from 5–50 mg/day over
14 days to normal human volunteers, decreased plasma
Aβ concentrations up to 40% in a dose-dependent man-
ner. Unfortunately however, CSF Aβ concentrations were
unchanged. Furthermore, at the 50 mg/d dose, adverse
events that were possibly drug-related were noted. R-flur-
biprofen is currently in phase III testing (N = 2400). In a
one-year phase II study (N = 207) of subjects with mild-
to-moderate AD receiving 400 mg b.i.d., 800 mg b.i.d., or
placebo, statistical significance was not reached in any
memory measures. However, a subset of mild patients
receiving the 800 mg b.i.d dose (who developed high
blood levels of the drug) demonstrated significant bene-
fits in activities of daily living and overall cognitive func-
tion [164]. A recent trial of the new NSAID, trifusal, which
also has γ-secretase inhibition activity, was also negative
[165]. The primary outcome measure was the change in
score on a cognitive assessment (an expanded version of
the ADAScog). Of course, these above-named negative tri-
als do not offer evidence that a different NSAID, anotherJournal of Neuroinflammation 2008, 5:51 http://www.jneuroinflammation.com/content/5/1/51
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dose, a different duration, or another study population
would not yield positive results. We and others have pre-
clinically examined three diverse therapies; all which
lower cerebral amyloid deposits: (1) Aβ immunization,
(2) human umbilical cord blood cell (HUBC) transplan-
tation, and (3) flavonoid supplementation, which we sug-
gest may show promise as combination or single
treatment(s) in AD patients.
Immunization against Aβ peptide was first explored by
Schenk and colleagues at Elan Pharmaceuticals. The vac-
cine was prepared from Aβ1–42 peptide (the presumed
pathogenic form of Aβ found in AD plaques) and com-
plete Freund's adjuvant. This original Aβ vaccine con-
ferred both therapeutic and prophylactic value in terms of
reducing CNS amyloid deposits in a transgenic mouse
model that overexpressed mutant human APP. In addi-
tion to augmenting adaptive immunity, the Elan vaccine
generated high-titre Aβ-specific antibodies [166]. The fol-
lowing year, another member of the team at Elan Pharma-
ceuticals reported a different version of the vaccine using
passive transfer of Aβ-specific antibodies to transgenic AD
mice [167]. This version of the vaccine was also effica-
cious, although less-so than the original "active" Aβ vac-
cine developed by Schenk and co-workers. Elan/Wyeth
then developed the vaccine for clinical trials in 2001 (AN-
1792), but approximately 6% of patients developed asep-
tic meningoencephalitis, which was most likely attributed
to brain infiltration of activated Aβ-specific T-cells. Two
years later, consent for long-term clinical follow-up, post-
mortem neuropathological examination, or both, was
sought from 80 patients (or their caretakers) who had
entered the original Elan AN-1792 phase I trial. The fol-
low-up study was completed in 2006. Twenty partici-
pants-15 in the AN1792 group, 5 in the placebo group-
died before follow-up started. A further 22 patients-19 in
the AN1792 group, three in the placebo group-died dur-
ing follow-up. Nine of the deceased subjects, all in the
AN1792 group, had given consent for post-mortem anal-
ysis; one of these who did not die with AD was excluded
[168]. In the remaining eight patients who received
immunization and who were examined neuropathologi-
cally, mean Aβ load was lower than in an unimmunised
control group matched for age at death (2.1% [SE 0.7] in
treated participants vs 5.1% [0.9] in controls; mean differ-
ence 3.0%, 95% CI 0.6–5.4; p = 0.02). Although there was
variation in load and degree of plaque removal among
immunized subjects, the degree of plaque removal varied
significantly with mean antibody response attained dur-
ing the treatment study period (Kruskal-Wallis p = 0.02).
Seven of the eight immunised patients who underwent
post-mortem assessment, including those with essentially
complete plaque removal, still had severe end stage
dementia before death. Further, in the whole cohort, there
was no evidence of improved survival (hazard ratio 0.93,
95% CI 0.43–3.11; p = 0.86) or of an extension of the time
until severe dementia (1.18, 0.45–3.11; p = 0.73) in the
AN1792 group versus the placebo group. Thus, it seems
that immunization lowered amyloid load but not progres-
sive neurodegeneration [168].
There have been a number of other attempts at Aβ vacci-
nation [169-172]. However, it should be noted that none
of these other Aβ vaccines have yet to be tested in humans,
and none of the Aβ vaccines tested in mice (with the
exception of one unconfirmed report) have produced the
meningoencephalitis that occurred in a subset of vacci-
nated AD patients [173]. Despite this limitation of the
mouse models, we have developed a transdermal method
to effectively deliver an Aβ vaccine. This version of the vac-
cine decreases cerebral amyloidosis and does not promote
infiltration of T-cells into the brain; but, again, the latter
data should be interpreted in the context of lack of brain
T-cell infiltrates in most AD mouse models receiving the
Aβ vaccine. Specifically, we designed and tested a novel
transcutaneous (t.c) Aβ1–42  vaccination strategy along
with cholera toxin (CT) as the adjuvant. The vaccine was
tested on wild-type mice as well as on PSAPP and Tg2657
transgenic mouse models of AD, which over-express
mutant human APP and develop brain β-amyloid
plaques. Additionally, the Tg2657 model develops AD-
like cerebral amyloid angiopathy (CAA); a pathology
which occurs in the majority of AD patients. We found
that the vaccine impacted both innate and adaptive
immunity in both wild-type and AD transgenic mice and
mitigated AD pathology in the transgenic mice [174].
The t.c. Aβ vaccine stimulated an innate immune response
in the non-transgenic mice as it caused LCs to migrate to
dermal layers containing the Aβ peptide. This response
was less frequently observed with administrations of CT
only or with PBS, suggesting that this effect may mediate
the initial immune response to the vaccine. In addition,
there is evidence from our experiments that the immuni-
zation stimulated an adaptive immune response as there
was an increase in Aβ antibody concentrations (particu-
larly of the IgG1 subtype) as well as Aβ-specific immune
responses in splenocytes from vaccinated mice. Since
IgG1 antibodies were produced at higher levels than
IgG2a or IgG2b, and since there was an 8-fold increase in
the secretion of the cardinal Th2 cytokine IL-4 from Aβ
"recall" challenged splenocytes, it seems that the t.c. Aβ
vaccine promotes an anti-inflammatory Th2 adaptive
immune response, which appears similar to the immune
responses observed by our group when employing an i.p.
Aβ vaccine protocol similar to the original Schenk and
colleagues report [175,176]. The AD mouse models pro-
duced a similar adaptive immune response after t.c. Aβ
vaccination, with increased concentrations of Aβ antibodyJournal of Neuroinflammation 2008, 5:51 http://www.jneuroinflammation.com/content/5/1/51
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and Aβ "recall" challenge-induced production of
cytokines by splenocytes.
The above-mentioned alterations in adaptive immunity
were associated with reduction of cerebral β-amyloid
deposits by 4G8 immunohistochemistry and Congo red
histochemistry, and levels of insoluble Aβ1–40,42  were
reduced by 50% and 54%, respectively. In addition, Aβ
deposits were reduced by 42–58% across hippocampal
and cortical areas, brain regions classically regarded as
most sensitive to AD-type pathological changes. It
deserves mentioning that we did not observe the negative
side-effects of cerebral T-cell infiltration (as detected by
CD3 antibody) or cerebral microhemorrhage; but, as
mentioned above for the former, most Aβ vaccines do not
produce this effect in mice. The lack of microhemorrhage
in the brains of mice receiving the t.c. Aβ vaccine suggests
that the Aβ antibody response was not pathogenic, as the
vaccine did not promote break-down of the blood-brain
barrier. We also observed an inverse correlation between
plasma and brain-soluble Aβ, signifying that circulating
Aβ antibodies may be important for clearing Aβ from the
brain to the blood; consistent with the "peripheral sink
hypothesis" of DeMattos and colleagues [177].
Modulating immunity in AD with human 
umbilical cord blood cells
Just as vaccination strategies modulate immunity in AD
by boosting adaptive immunity, human umbilical cord
blood cells (HUCBC) have been shown to have immu-
nomodulatory properties by opposing pro-inflammatory
Th1 and stimulating anti-inflammatory Th2 responses in
animal models of stroke and AD [178,179]. HUCBCs
have also shown therapeutic benefit in other neuroin-
flammatory conditions including multiple sclerosis,
amyotrophic lateral sclerosis, neurodegenerative macular
degeneration, and Parkinson's disease [180-182]. Our
recent study showed that intravenous HUCBC infusion
into transgenic AD mice resulted in diminished cerebral
Aβ/β-amyloid pathology and down-regulation of pro-
inflammatory responses in the brain and in the periphery
[183]. We attempted to localize HUCBCs to the brain, but
were unable to find CNS penetration of these cells, lead-
ing us to hypothesize that HUCBCs exerted their effect on
reducing cerebral amyloidosis by impacting host immune
responses. Although the exact mechanism is still
unknown, evidence strongly suggests this therapeutic
effect is accomplished by a diminution of Th1 and aug-
mentation of Th2 responses. Importantly, the CD40-
CD40L pathway is a key receptor/ligand dyad in initiating
and promoting the adaptive immune Th1 response and
innate immune responses in mononuclear cells. CD40
receptor, a member of the TNF and nerve growth factor
receptor super-family, is expressed on many professional
and non-professional APCs, including dendritic cells, B
cells, monocytes/macrophages and microglial cells [184-
188]. Furthermore, soluble CD40L was shown to be ele-
vated in MS and AD patients [189,190]. Based on the con-
spicuous role of the CD40-CD40L interaction in
mediating brain pro-inflammatory responses and exacer-
bating AD-like pathology, we investigated the impact of
HUCBC administration to AD mice on CD40 pathway-
mediated immune responses [186]. Our results show
decreased expression of microglial CD40 and reduction in
both CNS and peripheral sCD40L concomitant with
HUCBC-induced diminished AD-like pathology, raising
the possibility that disruption of CD40-CD40L interac-
tion may be responsible for mitigation of AD-like pathol-
ogy in this scenario [183]. These results are in accord with
those of Vendrame and colleagues, who observed that
HUCBC administration conferred rescue of behavioral
impairment and brain pathology in mouse models of
stroke via upregulation of Th2, and downregulation of
Th1 cytokine responses [178].
Flavonoids: a natural strategy to modulate 
immune responses in AD
A third means by which the aberrant pro-inflammatory
responses of inflammaging may be countered thereby
reducing AD severity is a group of natural plant-derived
compounds known as polyphenols; specifically those
known as "flavonoids" from the green tea plant. We and
others have focused on the treatment potential of a group
of flavonoids, which have been demonstrated to be both
anti-inflammatory and anti-amyloidogenic in the context
of AD [191-195]. Flavonoids are a large family of com-
pounds synthesized by plants that have a common chem-
ical structure [196]. Extensive analysis of the polyphenolic
components of green tea have been conducted. Green tea
flavonoids like epigallocatechin gallate (EGCG) appear to
promote downregulation of innate immune cell func-
tions. Putative mechanisms of flavonoid action on the
innate immune system include direct free radical scaveng-
ing [197,198] as well as reduction of inflammatory
cytokine production including TNF-α, IL-1β, and prostag-
landin E2 in response to LPS-induced activation [199]. In
accord with these findings, activated microglia co-cul-
tured with neuroblastoma cells were less neurotoxic in the
presence of the flavonoid fisetin, suggesting that some fla-
vonoids may act to inhibit proinflammatory innate
immune responses [200,201]. Some flavonoids, includ-
ing silibinin and EGCG, may modulate adaptive T-cell
mediated immune function by downregulating innate
immune stimulating cytokines that promote Th1 immu-
nity (e.g., TNF-α) and by promoting Th2 cytokines. These
effects are thought to be mediated in part via downregula-
tion of NFκB signaling [202-206]. Recently, we have
focused on three flavonoids as having therapeutic poten-
tial for AD: EGCG, luteolin, and diosmin.Journal of Neuroinflammation 2008, 5:51 http://www.jneuroinflammation.com/content/5/1/51
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EGCG inhibits TNF-α-induced production of monocyte
chemotactic protein-1 from vascular endothelial cells
[207]. Furthermore, EGCG also displays the ability to sup-
press neuron death mediated by activated microglia
[208]. Interestingly, green tea polyphenols and unripened
apple polyphenols appear to downregulate CD11b on
bovine peripheral monocytes, suggesting that leukocyte
adhesion and migration mediated in part by CD11b/
CD18 could be inhibited after treatment with these com-
pounds. In the same study, unripened apple polyphenols
upregulated CD11b on γδ T cells, indicating that these
compounds also act to modulate the adaptive immune
response [209]. In addition, EGCG suppresses endocy-
totic activity, and inhibits stimulatory activity toward all-
ogeneic T cells [166].
Most recently, we found that treatment of AD model neu-
rons (murine N2a cells transfected with the human
"Swedish" mutant form of APP) and primary neuronal
cells derived from AD model mice (the Tg2576 mouse
model of AD [211] with luteolin yielded significant reduc-
tion in Aβ generation [212]. This flavonoid achieves this
effect via selective inactivation of glycogen synthase kinase
3-alpha (GSK-3α). Additionally, we observed that admin-
istration of a structurally similar flavonoid, diosmin, to
Tg2576 mice similarly reduced Aβ generation, and this
effect seems to also occur through GSK-3 inhibition. Lute-
olin has been previously been shown to be a potent free
radical scavenger [213,214], anti-inflammatory agent
[215,216], and immunomodulator [217,218], and it is
possible that these latter two properties are owed to inhi-
bition of GSK-3. Luteolin is also associated with inhibi-
tion of NF-κB nuclear translocation, and p38 MAPK
signaling [219-221].
Although flavonoid-rich diets and flavonoid administra-
tion prevent cognitive impairment associated with
inflammaging in animal studies [222-225], retrospective
cohort studies are inconsistent in showing an inverse asso-
ciation between dietary flavonoid (e.g., green tea) intake
and dementia or neurodegenerative disease risk in
humans [226-229]. For example, an epidemiological
study of Dutch adults found total dietary flavonoid intake
was not associated with the risk of developing AD
[226,227], except in current smokers whose risk of AD
decreased by half for every 12 mg increase in daily flavo-
noid intake. On the other hand, elderly French men and
women with the lowest flavonoid intakes had a risk of
developing dementia over the next 5 years that was 50%
higher than those with the highest intakes [228]. Thus,
future human studies (ideally randomized clinical trials)
will be required which involve supplementation with rel-
atively high doses of specific purified flavanoids to shed
light on the apparent inverse risk relationship with AD
(and whether this occurs by reducing inflammaging) and
to determine if such compounds are therapeutically bene-
ficial.
Conclusion
In this review we have attempted to give a perspective on
the immunologic aspects of aging as they may relate to
AD, particularly the increased innate immunity by cells of
the mononuclear phagocyte lineage. While the over-active
innate immunity characteristic of inflammaging may
remain sub-clinical in many elderly individuals, in others
it may represent a significant risk for development of one
or more aging-associated diseases, including AD. Bringing
all this together, it is clear that the association between
inflammation, aging, and AD, as suggested by the wealth
of epidemiological, clinical and laboratory data, is based
on a series of complex molecular and cellular changes that
we are only just beginning to uncover and understand.
The initial signs are promising but further work is needed
in this area to research dietary, cell-based, and pharmaco-
logical strategies which oppose the features of inflammag-
ing and thus allow for prevention or treatment of AD.
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